Bristol-myers Squibb Compnay

Bristol-myers Company

Institute of Organic Chemistry and Biochemistry of the Academy of

Rega Stichting, V.z.w.

Shell Oil Comapny

Bristol-myers Squibb

Mitotix, Inc.

Muzammil M. Mansuri

John C. Martin

Thomas W. Hudyma

John E., Jr Starrett

Henry G. Howell

Carl E. Fuller

Muzammil M Mansuri

John E Starrett, Jr

John C Martin

Joanne J Bronson

David R Tortolani

Choung U Kim

Thomas W Hudyma

Stanley V D'Andrea

Peter F Misco

John A Wichtowski

Roman Z Sterzycki

Henry G Howell

Carl E Fuller

Nicholas A Meanwell

Yasutsugu Ueda

John D Matiskella

Kuo-Long Yu

Peter R Reczek

Shelley E Hoeft

Raymond F Miller

Katharine M Greene

Anita H Lewin

F Ivy Carroll

Kollol Pal

Dane M Springer

Bing-Yu Luh

Louis M Ferrara

Krishna K Murthi

Alasdair McArthur

Jr Starrett John E

This invention relates to a compound of formula I ##STR1## in which T is --CONH-- or --CH=CH--;

Heterocyclic-substituted naphthalenyl retinobenzoic acid derivatives

There are disclosed novel oral prodrugs of phosphonate nucleotide analogs which are hydrolyzable under physiological conditions to yield compounds which are useful as antiviral agents, especially as agents effective against RNA and DNA viruses. They may also find use as antitumor agents.

Prodrugs of phosphonates

A compound of the Formula I or Formula II ##STR1## wherein R.sup.1 and R.sup.2 are independently hydrogen, hydroxy, chlorine, fluorine, bromine, or an organic substituent having 1 to 5 carbon atoms and selected from acyloxy having a hydrocarbon stem of 1 to 4 carbon atoms, alkoxy, alkylthio, amino, alkylamino and dialkylamino;

Phosphonomethoxy carbocyclic nucleosides and nucleotides

Novel cephem derivatives represented by the general formula ##STR1## wherein Ar is an optionally substituted lipophilic phenyl, naphthyl, benzthiazolyl or pyridyl group; R.sup.1 represents a group of the formula ##STR2## in which R.sup.8 and R.sup.9 are each independently hydrogen, C.sub.1 -C.sub.6 alkyl or (C.sub.1 -C.sub.6)alkoxycarbonyl, said C.sub.1 -C.sub.6 alkyl group being optionally substituted by 1-5 hydroxy or C.sub.1 -C.sub.6 alkoxy groups; m is either 0 or 1; A is a C.sub.2 -C.sub.10 alkyl group optionally substituted by 1-5 hydroxy groups; and R.sup.2 and R.sup.3 are each independently hydrogen or C.sub.1 -C.sub.6 alkyl. The derivatives are gram-positive antibacterial agents especially useful in the treatment of diseases caused by methicillin-resistant Staphylococcus aureus.

Cephalosporin derivatives

The invention provides novel inhibitors of cyclin-dependent kinases, in particular inhibitors of the CDK/cyclin complexes such as CDK4/cyclin D1. The novel compounds are analogs of chromones. These compounds can be used for inhibiting excessive or abnormal cell proliferation. Thus, the novel compounds are useful for treating a subject with a disorder associated with excessive cell proliferation, such as cancer.

Inhibitors of cyclin dependent kinases

Novel cephem derivatives represented by the general formula ##STR1## in which the Acyl substituent is a group of the formula ##STR2## wherein Ar is a lipophilic optionally substituted phenyl, naphthyl, pyridyl or benzthiazolyl group; R.sup.1 is selected from certain optionally substituted aliphatic, aromatic, arylaliphatic or sugar moieties and R.sup.2 and R.sup.3 are each independently hydrogen, alkyl or aminoalkylcarbonylamino are gram-positive antibacterial agents, especially useful in the treatment of infectious diseases caused by methicillin-resistant Staphylococcus aureus (MRSA).

The present invention relates to a compound of formula ##STR1## or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, in which

Retinoid-like compounds

The present invention relates to a compound of formula I ##STR1## or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, in which

Pyridinium thiomethyl substituted chepholosporin derivatives

Novel cephem derivatives represented by the general formula ##STR1## in which the Acyl substituent is a group of the formula ##STR2## where Ar is a substituted phenyl or optionally substituted naphthyl or benzthiazolyl group and A is a substituted-pyridinium group are gram-positive antibiotics, especially useful in the treatment of diseases caused by methicillin-resistant Staphylococcus aureus.

This invention relates to a compound of formula I ##STR1## in which T is --CONH-- or --CH.dbd.CH--;

Retinoid-like heterocycles

This invention relates to a retinoid mpound of formula I ##STR1## in which Y is --CO--NH--, --CR.sup.2 .dbd.CR.sup.3 --, --CO--O--, --O--CO--, --C(.dbd.S)--NH--, --C.tbd.C--, --O--CH.sub.2 --, --CH.sub.2 --O--, or --CH.sub.2 --CH.sub.2 --;

Certain novel alicyclic compounds are effective phospholipase A.sub.2 (PLA.sub.2) inhibitors.

Alicyclic phospholipase A.sub.2 inhibitors

Certain novel biaryl compounds are effective phospholipase A.sub.2 (PLA.sub.2) inhibitors.

Biaryl phospholipase A.sub.2 inhibitors

Growing community of inventors

Cheshire, CT, United States of America

Muzammil M Mansuri